Is Capmatinib a chemotherapy drug?

Capmatinib is a targeted drug, is a small drug targeting c-Met Molecular kinase inhibitor for the treatment of Metexon14 skipped non-small cell lung cancer.

Capmatinib inhibits the excessive activity of c-Met, a receptor tyrosine kinase encoded by the Met proto-oncogene. MET mutations are associated with proliferation in many cancers, including non-small cell lung cancer. Capmatinibshowed good central nervous system activity, with an intracranial response rate of 54%. Although regulatory approval did not extend to MET tumors, 29–40% of MET were highly amplified (gene copy number ≥ 10) patients with non-small cell lung cancer had an objective response tocapmatinib.

Capmatinib inhibits the excessive activity of c-Met, a receptor tyrosine kinase encoded by the Met proto-oncogene. Metmutations are associated with the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinibmay cause photosensitivity reactions in patients following ultraviolet (UV) exposure-Patients receiving Capmatinib should be advised to use sunscreen and protective clothing to limit UV radiation exposure. Cases of potentially fatal interstitial lung disease/pneumonia have occurred in patients treated with capmatinib. Capmatinib should be discontinued immediately in patients who develop signs or symptoms of pulmonary disease (e.g., cough, dyspnea, fever) or permanently if no other feasible cause of the pulmonary-related symptoms is identified. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0